173.78
price up icon2.36%   3.62
after-market Handel nachbörslich: 174.20 0.42 +0.24%
loading

Abbvie Inc Aktie (ABBV) Neueste Nachrichten

pulisher
11:13 AM

Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom - Barron's

11:13 AM
pulisher
10:46 AM

AbbVie (ABBV) Has a New Rating from Scotiabank - The Globe and Mail

10:46 AM
pulisher
10:22 AM

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy - Baystreet.ca

10:22 AM
pulisher
09:06 AM

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast? - TradingView

09:06 AM
pulisher
08:30 AM

Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't? - Yahoo Finance

08:30 AM
pulisher
07:37 AM

This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

07:37 AM
pulisher
07:34 AM

AbbVie (ABBV) Initiated at Overweight by Cantor Fitzgerald with $210 Price Target | ABBV Stock News - GuruFocus

07:34 AM
pulisher
06:55 AM

AbbVie price target lowered to $200 from $223 at BofA - TipRanks

06:55 AM
pulisher
Apr 21, 2025

Lobbying Update: $2,110,000 of ABBVIE INC. lobbying was just disclosed - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

AbbVie (ABBV) Stock Moves -1.64%: What You Should Know - Yahoo Finance

Apr 21, 2025
pulisher
Apr 21, 2025

Jim Cramer Is Bullish on AbbVie Inc. (ABBV) Ahead of Earnings - Insider Monkey

Apr 21, 2025
pulisher
Apr 21, 2025

BofA Adjusts AbbVie (ABBV) Price Target Ahead of Q1 Results | ABBV Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Immunology Drugs Market Top Companies Study- Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer. - openPR.com

Apr 21, 2025
pulisher
Apr 21, 2025

The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com

Apr 21, 2025
pulisher
Apr 20, 2025

Is AbbVie Stock a Buy? - MSN

Apr 20, 2025
pulisher
Apr 19, 2025

Lobbying Update: $50,000 of ABBVIE INC. lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 19, 2025

Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey

Apr 19, 2025
pulisher
Apr 18, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 18, 2025
pulisher
Apr 18, 2025

CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView

Apr 18, 2025
pulisher
Apr 18, 2025

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView

Apr 18, 2025
pulisher
Apr 18, 2025

Is AbbVie Inc. (ABBV) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey

Apr 18, 2025
pulisher
Apr 18, 2025

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

AbbVie Inc. (NYSE:ABBV) Shares Sold by Canada Pension Plan Investment Board - MarketBeat

Apr 18, 2025
pulisher
Apr 18, 2025

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - marketscreener.com

Apr 18, 2025
pulisher
Apr 18, 2025

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.

Apr 18, 2025
pulisher
Apr 17, 2025

AbbVie (ABBV): A Top Dividend Monarch with Strong Growth Prospects - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Applications now open for Abbvie’s cystic fibrosis scholarship program - Cystic Fibrosis News Today

Apr 17, 2025
pulisher
Apr 17, 2025

AbbVie (ABBV) Gets a Buy from Guggenheim - The Globe and Mail

Apr 17, 2025
pulisher
Apr 17, 2025

Fund Update: Bank Pictet & Cie (Europe) AG added 78,930 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey

Apr 17, 2025
pulisher
Apr 17, 2025

ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com

Apr 17, 2025
pulisher
Apr 16, 2025

AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

10 Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey

Apr 16, 2025
pulisher
Apr 16, 2025

AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now - Insider Monkey

Apr 16, 2025
pulisher
Apr 16, 2025

Interleukin Inhibitors Market Is Booming Worldwide | AbbVie - openPR.com

Apr 16, 2025
pulisher
Apr 16, 2025

Drug company files suit against South Dakota over new 340B law - South Dakota Public Broadcasting

Apr 16, 2025
pulisher
Apr 16, 2025

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

Top Research Reports for AbbVie, TJX & Charles Schwab - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

AbbVie Asks Court to Extend Venclexta Cancer-Drug Patent’s Life - Bloomberg Law News

Apr 15, 2025
pulisher
Apr 15, 2025

AbbVie Options Trading: A Deep Dive into Market Sentiment - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

Drugmaker sues SD over law preserving broad access to discounts for hospitals, pharmacies - Argus Leader

Apr 15, 2025
pulisher
Apr 15, 2025

The Zacks Analyst Blog Merck and AbbVie - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey

Apr 15, 2025
pulisher
Apr 14, 2025

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 14, 2025
pulisher
Apr 14, 2025

AbbVie and Sandoz agree to drop court spat over Rinvoq patents - Endpoints News

Apr 14, 2025
pulisher
Apr 14, 2025

ABBV vs. MRK: Which Drug Giant is a Better Buy Now? - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com

Apr 14, 2025
pulisher
Apr 14, 2025

The Zacks Analyst Blog Merck And AbbVie - Barchart.com

Apr 14, 2025
pulisher
Apr 14, 2025

Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Earnings Preview: What to Expect From AbbVie's Report - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Earnings Preview: What To Expect From AbbVie's Report - Barchart.com

Apr 14, 2025
pulisher
Apr 14, 2025

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

10 High Growth Forever Dividend Stocks To Invest In - Insider Monkey

Apr 14, 2025
pulisher
Apr 13, 2025

Is AbbVie Inc. (ABBV) the Best Stock for 15 Years? - Insider Monkey

Apr 13, 2025
drug_manufacturers_general NVO
$59.91
price up icon 2.58%
drug_manufacturers_general JNJ
$157.75
price up icon 0.54%
drug_manufacturers_general NVS
$111.41
price up icon 0.77%
drug_manufacturers_general MRK
$78.97
price up icon 1.24%
$278.40
price up icon 1.69%
Kapitalisierung:     |  Volumen (24h):